Some Experts Concerned New Brand-Name PrEP Drug May Decrease Access To Such Treatment If It’s Favored By Clinicians Over New Generic Version Of Older PrEP Drug

Reuters (3/9, Rapaport) reports a paper published in the Annals of Internal Medicine suggests that access to PrEP may decline if physicians begin prescribing a newer, more expensive brand-name version rather than an older PrEP treatment that now has a gen...